Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen
We report on a patient with ciltacabtagene autoleucel-induced movement and neurocognitive toxicity, which was refractory to immunosuppression but responsive to combination dopaminergic therapy (carbidopa/levodopa, ropinirole, amantadine). Response was seen upon both initial treatment and rechallenge after unintended withdrawal. This is the first report of a successful symptomatic treatment of this well-described neurotoxic syndrome.
Authors
- Xenos Mason (ORCID: https://orcid.org/0000-0002-5821-7275)
- Scott Goldsmith (ORCID: https://orcid.org/0000-0001-9216-2418)
- Michael Rosenzweig (ORCID: https://orcid.org/0000-0001-5158-5131)
- Olga Manouvakhova (ORCID: https://orcid.org/0000-0001-5933-7378)
- Murali Janakiram (ORCID: https://orcid.org/0000-0001-9323-8007)
- Myo Htut
- Johannes Pulst‐Korenberg
- Cindy Wong
- Raya Aliakbar
Institutions
- University of Southern California (US)
- City of Hope (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.3389/fimmu.2024.1444010
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.26